ArticleJournal of nanobiotechnology2026
ROS-responsive nanoliposomes loaded with anti-oomycetes medium-chain fatty acids for shuttling delivery in plant disease control.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
background2E,4E-decadienoic acid (DDA) is an aliphatic compound with potent anti‑oomycete activity against Phytophthora nicotianae (Pn), a plant pathogen responsible for major agricultural losses. Mechanistic studies revealed that DDA targets mitochondria and requires intracellular delivery to exert its activity. To improve its stability and bioavailability, we developed a reactive oxygen species (ROS)-responsive, TAT‑peptide (P) ‑modified liposomal (Lipo) delivery system (DDA@P‑ROS‑Lipo) containing thioketal (TK) linkages that cleave under elevated ROS conditions during pathogen infection, enabling controlled and site‑specific release of DDA. The TAT peptide, as a cell‑penetrating moiety, markedly enhanced intracellular uptake.
resultsThe resulting nanoparticles exhibited an average hydrodynamic diameter of approximately 112 nm and a high DDA encapsulation efficiency of 80.84%. They also demonstrated excellent photostability, making the formulation suitable for field application. The nanoscale size and strong affinity for tobacco leaf surfaces reduced the contact angle, thereby improving adherence and deposition. Compared with free DDA, the nanoformulation enhanced mycelial inhibition by 45% and achieved superior control of tobacco black shank disease in pot experiments. Both in vitro cytotoxicity and in vivo zebrafish toxicity assays confirmed the safety of the formulation.
conclusionThis work presents a simple and effective strategy for the targeted delivery of anti‑oomycete agents. DDA@P‑ROS‑Lipo offers a green and efficient approach for plant disease management under controlled conditions, and future studies will explore its scalability and performance in field environments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.